Cargando…
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients
BACKGROUND: Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer pat...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997727/ https://www.ncbi.nlm.nih.gov/pubmed/33882374 http://dx.doi.org/10.1016/j.ejca.2021.03.033 |
_version_ | 1783670393296388096 |
---|---|
author | Mansi, Laura Spehner, Laurie Daguindau, Etienne Bouiller, Kevin Almotlak, Hamadi Stein, Ulrich Bouard, Adeline Kim, Stefano Klajer, Elodie Jary, Marine Meynard, Guillaume Vienot, Angélique Nardin, Charlée Bazan, Fernando Lepiller, Quentin Westeel, Virginie Adotévi, Olivier Borg, Christophe Kroemer, Marie |
author_facet | Mansi, Laura Spehner, Laurie Daguindau, Etienne Bouiller, Kevin Almotlak, Hamadi Stein, Ulrich Bouard, Adeline Kim, Stefano Klajer, Elodie Jary, Marine Meynard, Guillaume Vienot, Angélique Nardin, Charlée Bazan, Fernando Lepiller, Quentin Westeel, Virginie Adotévi, Olivier Borg, Christophe Kroemer, Marie |
author_sort | Mansi, Laura |
collection | PubMed |
description | BACKGROUND: Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients’ immune system responds to SARS-CoV-2 virus. METHODS: We have started a prospective monocentric trial entitled COV-CREM (NCT04365322) in April 2020. The primary objective of the trial was to assess specific immune response's intensity and diversity to SARS-CoV-2 in infected patients. RESULTS: In this study, we showed that cancer patients (28 solid tumours, 11 haematological malignancies) exposed to SARS-CoV-2 produced a high rate of specific antibodies, as observed in patients without a cancer history (n = 29). However, our results highlight a lack in the generation of T-cell responses against CoV–N, M and S proteins from the SARS-CoV-2 virus, suggesting that cancer patients failed to mount a protective T-cell immunity. Nevertheless, SARS-CoV-2 infection did not impair established immune memory since specific responses against common viruses were not hampered in cancer patients. CONCLUSION: Given the severity and the unknown evolution of the ongoing COVID-19 pandemic, it is of fundamental importance to integrate cancer patients in vaccination programs. |
format | Online Article Text |
id | pubmed-7997727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79977272021-03-29 Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients Mansi, Laura Spehner, Laurie Daguindau, Etienne Bouiller, Kevin Almotlak, Hamadi Stein, Ulrich Bouard, Adeline Kim, Stefano Klajer, Elodie Jary, Marine Meynard, Guillaume Vienot, Angélique Nardin, Charlée Bazan, Fernando Lepiller, Quentin Westeel, Virginie Adotévi, Olivier Borg, Christophe Kroemer, Marie Eur J Cancer Current Perspective BACKGROUND: Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients’ immune system responds to SARS-CoV-2 virus. METHODS: We have started a prospective monocentric trial entitled COV-CREM (NCT04365322) in April 2020. The primary objective of the trial was to assess specific immune response's intensity and diversity to SARS-CoV-2 in infected patients. RESULTS: In this study, we showed that cancer patients (28 solid tumours, 11 haematological malignancies) exposed to SARS-CoV-2 produced a high rate of specific antibodies, as observed in patients without a cancer history (n = 29). However, our results highlight a lack in the generation of T-cell responses against CoV–N, M and S proteins from the SARS-CoV-2 virus, suggesting that cancer patients failed to mount a protective T-cell immunity. Nevertheless, SARS-CoV-2 infection did not impair established immune memory since specific responses against common viruses were not hampered in cancer patients. CONCLUSION: Given the severity and the unknown evolution of the ongoing COVID-19 pandemic, it is of fundamental importance to integrate cancer patients in vaccination programs. Elsevier Ltd. 2021-06 2021-03-26 /pmc/articles/PMC7997727/ /pubmed/33882374 http://dx.doi.org/10.1016/j.ejca.2021.03.033 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Current Perspective Mansi, Laura Spehner, Laurie Daguindau, Etienne Bouiller, Kevin Almotlak, Hamadi Stein, Ulrich Bouard, Adeline Kim, Stefano Klajer, Elodie Jary, Marine Meynard, Guillaume Vienot, Angélique Nardin, Charlée Bazan, Fernando Lepiller, Quentin Westeel, Virginie Adotévi, Olivier Borg, Christophe Kroemer, Marie Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients |
title | Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients |
title_full | Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients |
title_fullStr | Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients |
title_full_unstemmed | Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients |
title_short | Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients |
title_sort | study of the sars-cov-2-specific immune t-cell responses in covid-19-positive cancer patients |
topic | Current Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997727/ https://www.ncbi.nlm.nih.gov/pubmed/33882374 http://dx.doi.org/10.1016/j.ejca.2021.03.033 |
work_keys_str_mv | AT mansilaura studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT spehnerlaurie studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT daguindauetienne studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT bouillerkevin studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT almotlakhamadi studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT steinulrich studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT bouardadeline studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT kimstefano studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT klajerelodie studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT jarymarine studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT meynardguillaume studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT vienotangelique studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT nardincharlee studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT bazanfernando studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT lepillerquentin studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT westeelvirginie studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT adoteviolivier studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT borgchristophe studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients AT kroemermarie studyofthesarscov2specificimmunetcellresponsesincovid19positivecancerpatients |